|
|
|
|
|
|
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
An Open Label Phase I Dose Finding Study of BI 860585 Administered Orally in a Continuous Dosing Schedule as Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumours
The primary objective of the trial is to determine the maximum tolerated doses (MTD) of BI 860585 alone and in combination with exemestane or paclitaxel. To determine the MTDs, patients are entered sequentially into escalating dose cohorts. Secondary objectives are objective response and disease control according to RECIST criteria version 1.1
100 项与 mTORC1 x Nav1.7 x mTORC2 相关的临床结果
100 项与 mTORC1 x Nav1.7 x mTORC2 相关的转化医学
0 项与 mTORC1 x Nav1.7 x mTORC2 相关的专利(医药)